At ASCO 2017, two trials tackled important surgical questions in ovarian cancer management, with the potential to eventually change practice, according to Dr Maurie Markman.

Dr Peter Bach attributes the high cost of cancer drugs to the pharmaceutical industry's 'government-granted monopoly pricing power,' saying that benefit to patients is not commensurate with price.

Oncologists will debate the APHINITY trial data for years to come, says Dr Kevin Kalinsky.

At ASCO 2017, experts provided practical tips for oncologists to develop resilience and prevent burnout in their professional lives.

Dr Maurie Markman discusses new research on therapy for low-grade serous cancer of the ovary from the Journal of Clinical Oncology.

According to Dr Kris, new ASCO guidelines for adjuvant management of NSCLC stress the importance of multimodality care.

At ASCO 2017, the MONARCH-3, PALOMA-1, AND TREnd trials shed light on the efficacy of new CDK4/6 inhibitors for metastatic breast cancer.

Dr Laura Esserman discusses the ground-breaking I-SPY breast cancer research platform and its most 'exciting' results to date, indicating that pembrolizumab triples pCR in TNBC.

Dr John Marshall reports on the practice-changing results of the IDEA study in stage III colorectal cancer looking at duration of adjuvant chemotherapy, as presented at the ASCO plenary session.

Study author Dr Susan Domchek discusses the positive results of the OlympiAD trial, presented at the ASCO plenary session, indicating olaparib as a strong option in metastatic breast cancer.